Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$21.88 USD
-1.05 (-4.58%)
Updated Sep 20, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Earnings News For NTLA
-
Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates
-
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
-
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
-
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
-
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
-
Intellia (NTLA) to Report Q1 Earnings: What's in the Cards?
-
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
-
Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update
-
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
-
Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update
-
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Intellia (NTLA) Misses on Q2 Earnings, Gives Pipeline Update
-
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Misses Revenue Estimates
-
Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update
-
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Lags Revenue Estimates
-
Intellia's (NTLA) Q4 Loss Matches Estimates, Revenues Up Y/Y
-
Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
-
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Should You Buy?
-
Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y
-
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates
-
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Intellia's (NTLA) Q2 Loss Wider Than Expected, Revenues Beat
-
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates
-
Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat
-
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates